Description
CZC-54252 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2) that exhibits neuroprotective activity. This compound may decrease neuronal injury in models of neurodegenerative diseases such as Parkinson’s disease.
Product Info
| Cas No. | 1191911-27-9 |
|---|---|
| Purity | ≥98% |
| Formula | C22H25ClN6O4S |
| Formula Wt. | 504.99 |
| Chemical Name | N-{2-[(5-chloro-2-{[2-methoxy-4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}methanesulfonamide |
| IUPAC Name | N-{2-[(5-Chloro-2-{[2-methoxy-4-(4-morpholinyl)phenyl]amino}-4-pyrimidinyl)amino]phenyl}methanesulfonamide |
| Synonym | SCHEMBL1460537; CHEBI:78414; BCP15148 |
| Solubility | 100mM in DMSO |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
References
Kramer T, Lo Monte F, Göring S, et al. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chem Neurosci. 2012 Mar 21;3(3):151-60. PMID: 22860184.
Ramsden N, Perrin J, Ren Z, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8. PMID: 21812418.